- Home
- NRXS vs CANF Comparison
NRXS vs CANF Comparison
Compare NRXS & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- CANF
- Stock Information
- Founded
- NRXS 2011
- CANF 1994
- Country
- NRXS United States
- CANF Israel
- Employees
- NRXS N/A
- CANF N/A
- Industry
- NRXS
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- CANF Health Care
- Exchange
- NRXS Nasdaq
- CANF Nasdaq
- Market Cap
- NRXS 13.0M
- CANF 14.8M
- IPO Year
- NRXS 2023
- CANF N/A
- Fundamental
- Price
- NRXS $2.60
- CANF $1.02
- Analyst Decision
- NRXS Strong Buy
- CANF Strong Buy
- Analyst Count
- NRXS 1
- CANF 2
- Target Price
- NRXS $7.00
- CANF $14.00
- AVG Volume (30 Days)
- NRXS 137.3K
- CANF 146.1K
- Earning Date
- NRXS 08-08-2025
- CANF 08-29-2025
- Dividend Yield
- NRXS N/A
- CANF N/A
- EPS Growth
- NRXS N/A
- CANF N/A
- EPS
- NRXS N/A
- CANF N/A
- Revenue
- NRXS $2,934,945.00
- CANF $674,000.00
- Revenue This Year
- NRXS $138,883.78
- CANF $461.72
- Revenue Next Year
- NRXS $118.59
- CANF N/A
- P/E Ratio
- NRXS N/A
- CANF N/A
- Revenue Growth
- NRXS 27.52
- CANF N/A
- 52 Week Low
- NRXS $1.33
- CANF $0.98
- 52 Week High
- NRXS $6.20
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- NRXS 52.91
- CANF 39.13
- Support Level
- NRXS $2.32
- CANF $0.99
- Resistance Level
- NRXS $2.65
- CANF $1.09
- Average True Range (ATR)
- NRXS 0.15
- CANF 0.04
- MACD
- NRXS -0.01
- CANF -0.00
- Stochastic Oscillator
- NRXS 78.05
- CANF 16.67
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).